Workflow
STRATA Skin Sciences(SSKN)
icon
Search documents
STRATA Skin Sciences' TheraClear®X Acne Therapy System Found Safe and Effective in Study Published in Peer Reviewed Journal
Newsfilter· 2024-07-17 12:00
HORSHAM, Pa., July 17, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces the publication of a clinical study titled, "Advancing precision acne therapy using a photopneumatic device," in the July 11, 2024 issue of the Journal of Cosmetic and Laser Therapy. All patients experienced a visible reduction in co ...
STRATA Skin Sciences Sponsors Webinars Featuring Leading Dermatologists Discussing Benefits of XTRAC® and TheraClear®X Devices
Newsfilter· 2024-06-12 12:00
HORSHAM, Penn., June 12, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces the availability of two virtual webinars that discuss the benefits of using its XTRAC® excimer device for the treatment of psoriasis, vitiligo, and eczema and its TheraClear®X photopneumatic device for the treatment of mild to mode ...
STRATA Skin Sciences' TheraClear®X Acne Therapy System Found to be Safe and Effective for Acne Lesions Across All Fitzpatrick Skin Types with Favorable Tolerability and Patient Satisfaction as Published in Peer Reviewed Journal
Newsfilter· 2024-06-07 12:15
Significant reduction in acne lesion counts at each visit compared to the baseline. ≥1 grade reduction in Investigator's Global Assessment (IGA) for two-thirds (20/30) of participants by Day 49. Visible improvements as early as after 3 treatments. Consistent enhancements in patient Acne Quality of Life and satisfaction scores across all time points. Well-tolerated treatments with no treatment-related adverse events. High treatments satisfaction with 80% of participants reported being satisfied or very satis ...
STRATA Skin Sciences' TheraClear®X Acne Therapy System Found to be Safe and Effective for Acne Lesions Across All Fitzpatrick Skin Types with Favorable Tolerability and Patient Satisfaction as Published in Peer Reviewed Journal
GlobeNewswire News Room· 2024-06-07 12:15
Dr. Ablon noted, "I am thrilled with the clinical study results for TheraClearX Acne System. The data clearly demonstrates TheraClear®X's efficacy and safety, providing a significant improvement for Acne patients. Noninvasive devices are always needed in the acne armamentarium!" Safe Harbor The study concluded that photopneumatic monotherapy effectively reduces acne lesions across all Fitzpatrick skin types with favorable tolerability and participant satisfaction. Customizable settings allow tailored treatm ...
STRATA Skin Sciences to Participate in June Dermatology Conferences
GlobeNewswire News Room· 2024-06-04 12:00
HORSHAM, Penn., June 04, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces its participation in two dermatology conferences in the month of June. On June 1, STRATA has participated in the inaugural Schweiger Symposium at the Jacob Javits Center in New York City. The Symposium brought together dermatology ...
STRATA Skin Sciences(SSKN) - 2024 Q1 - Earnings Call Transcript
2024-05-16 02:08
STRATA Skin Sciences, Inc. (NASDAQ:SSKN) Q1 2024 Results Conference Call May 2, 2024 4:30 PM ET Company Participants Dolev Rafaeli - Chief Executive Officer Chris Lesovitz - Chief Financial Officer Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann & Co. Operator Ladies and gentlemen, thank you for standing by. Good afternoon, and welcome to the STRATA Skin Sciences Inc. First Quarter of 2024 Financial Results and Corporate Update Conference Call. [Operator Instructions] A webcast replay of the ...
STRATA Skin Sciences(SSKN) - 2024 Q1 - Quarterly Report
2024-05-15 20:33
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 0-51481 STRATA SKIN SCIENCES, INC. (Exact name of registrant as specified in its charter) | Delaware | 13-3986004 | | --- | --- | | (State or Other Jurisdiction of incorporati ...
STRATA Skin Sciences(SSKN) - 2024 Q1 - Quarterly Results
2024-05-15 20:30
Exhibit 99.1 STRATA Skin Sciences Reports First Quarter 2024 Financial Results and Provides a Corporate Update HORSHAM, Penn., May 15, 2024 – STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces its financial results for the quarter ended March 31, 2024 and provides a corporate update. First Quarter 2024 Highlights • Revenue in the ...
STRATA Skin Sciences(SSKN) - 2023 Q4 - Earnings Call Transcript
2024-03-28 02:03
STRATA Skin Sciences, Inc. (NASDAQ:SSKN) Q4 2023 Earnings Conference Call March 27, 2024 4:30 PM ET Company Participants Rich Cockrell - Investor Relations Dolev Rafaeli - President & Chief Executive Officer Christopher Lesovitz - Chief Financial Officer Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann Operator Greetings, and welcome to the STRATA Skin Sciences' Fourth Quarter 2023 Earnings Conference Call and Webcast. At this time, all participants are in a listen-only mode. A brief question ...
STRATA Skin Sciences(SSKN) - 2023 Q4 - Annual Report
2024-03-28 00:06
OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such short ...